CD20
Other names: CD20 positive
CD20 is a classic marker in B-cell lymphoma and is the basis for a major antibody therapy group.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Plain explanation
CD20 is a protein on the surface of B cells that has long been used to identify B cell lymphoma in pathological examinations.
Clinical meaning
CD20 positivity helps confirm the tumor cell origin and is a consideration in the category of anti-CD20 antibody therapy, including in B-cell non-Hodgkin lymphoma.
Testing methods
- Immunohistochemistry (IHC)
A test that uses antibodies to mark specific proteins in tumour tissue.
- Flow cytometry
A test that rapidly measures cell-surface markers across many cells.
- Tumour tissue biopsy
Collection of tumour tissue to confirm the diagnosis and provide material for further testing.
A negative result does not always mean the marker is absent
Test sensitivity differs by sample type and method. Results need to be read together with the pathology report and clinical condition.
What needs verification
- Immunohistochemistry report confirming CD20 positivity.
- Classify lymphoma specifically, not just a common name.
- History of previous anti-CD20 therapy and response.
- Availability of drugs and suitability of financing.
Related drugs
- Rituximab
Anti-CD20 monoclonal antibody
- Obinutuzumab
Second generation anti-CD20 monoclonal antibody
- Polatuzumab vedotin
Anti-CD79b antibody-drug conjugate
- Mosunetuzumab
CD20xCD3 bispecific antibody
- Glofitamab
CD20xCD3 bispecific antibody
A link here means the marker is often part of considering a drug category, not a recommendation to use it.
Guides discussing this marker
- Relapsed DLBCL: when CAR-T starts being discussed9 min read
- Reading a pathology report: which parts matter most6 min read
Written to help prepare questions and documents, not to replace a doctor's assessment.
Clinical trials
Studies mentioning this marker
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT07308132Phase 1Immunotherapy
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Lymphoma | biomarker: CD20 | Immunotherapy, Chemotherapy
Australia, Belgium, France +219 registry sites
Why this appears: Appears because it is recorded for Lymphoma, it mentions marker CD20, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07308132Not verified
Check options based on your result
Share the CD20 result you have so we can explain which categories to discuss with a doctor.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Leukemia
Subtype
Reason: Related through a biomarker
- Lymphoma
Cancer type
Reason: Related through a biomarker
- Immunotherapy
Treatment category
Reason: Related through a biomarker
- Chemotherapy
Treatment category
Reason: Related through a biomarker
- Glofitamab
Drug
Reason: Targets this marker
- Mosunetuzumab
Drug
Reason: Targets this marker
To check
- Tumour tissue biopsy
Diagnostic test
Reason: Diperiksa melalui
- Flow cytometry
Diagnostic test
Reason: Diperiksa melalui
- Immunohistochemistry (IHC)
Diagnostic test
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.